Table 7.
Open in new tab

Correlation of AUC in male and female patients with CAH and controls

Males
17OHPA411OHA4T11KT
Patients 17OHP-0.798****0.633***0.3310.773****
A40.798****-0.659**0.555**0.637***
11OHA40.633***0.659**-0.2240.613***
T0.3310.555**0.224-0.016
11KT0.773****0.637***0.613***0.016-
17OHPA411OHA4T11KT
Controls17OHP-0.780***0.2760.622**0.203
A40.780***-0.3400.814****0.249
11OHA40.2760.340--0.0100.806****
T0.622**0.814****-0.010--0.032
11KT0.2030.2490.806****-0.032-
Females
17OHPA411OHA4T11KT
Patients 17OHP-0.695****0.564*0.614***0.737****
A40.695****-0.450*0.868****0.697****
11OHA40.564**0.450*-0.470*0.764****
T0.614***0.868****0.470*-0.631***
11KT0.737****0.697****0.764****0.631***-
17OHPA411OHA4T11KT
Controls17OHP-0.597**0.2330.874****0.419
A40.597**-0.3670.693****0.159
11OHA40.2330.367-0.1480.109
T0.874****0.693****0.148-0.276
11KT0.419*0.1590.1090.276-
Males
17OHPA411OHA4T11KT
Patients 17OHP-0.798****0.633***0.3310.773****
A40.798****-0.659**0.555**0.637***
11OHA40.633***0.659**-0.2240.613***
T0.3310.555**0.224-0.016
11KT0.773****0.637***0.613***0.016-
17OHPA411OHA4T11KT
Controls17OHP-0.780***0.2760.622**0.203
A40.780***-0.3400.814****0.249
11OHA40.2760.340--0.0100.806****
T0.622**0.814****-0.010--0.032
11KT0.2030.2490.806****-0.032-
Females
17OHPA411OHA4T11KT
Patients 17OHP-0.695****0.564*0.614***0.737****
A40.695****-0.450*0.868****0.697****
11OHA40.564**0.450*-0.470*0.764****
T0.614***0.868****0.470*-0.631***
11KT0.737****0.697****0.764****0.631***-
17OHPA411OHA4T11KT
Controls17OHP-0.597**0.2330.874****0.419
A40.597**-0.3670.693****0.159
11OHA40.2330.367-0.1480.109
T0.874****0.693****0.148-0.276
11KT0.419*0.1590.1090.276-

Spearman’s correlation coefficient r. P value ≤ 0.05 (*), ≤0.01 (**), ≤0.001 (***), ≤0.0001 (****).

Abbreviations: 11KT, 11-ketotestosterone; 11OHA4, 11β-hydroxyandrostenedione; 17OHP, 17-hydroxyprogesterone; A4, androstenedione; T, testosterone.

Table 7.
Open in new tab

Correlation of AUC in male and female patients with CAH and controls

Males
17OHPA411OHA4T11KT
Patients 17OHP-0.798****0.633***0.3310.773****
A40.798****-0.659**0.555**0.637***
11OHA40.633***0.659**-0.2240.613***
T0.3310.555**0.224-0.016
11KT0.773****0.637***0.613***0.016-
17OHPA411OHA4T11KT
Controls17OHP-0.780***0.2760.622**0.203
A40.780***-0.3400.814****0.249
11OHA40.2760.340--0.0100.806****
T0.622**0.814****-0.010--0.032
11KT0.2030.2490.806****-0.032-
Females
17OHPA411OHA4T11KT
Patients 17OHP-0.695****0.564*0.614***0.737****
A40.695****-0.450*0.868****0.697****
11OHA40.564**0.450*-0.470*0.764****
T0.614***0.868****0.470*-0.631***
11KT0.737****0.697****0.764****0.631***-
17OHPA411OHA4T11KT
Controls17OHP-0.597**0.2330.874****0.419
A40.597**-0.3670.693****0.159
11OHA40.2330.367-0.1480.109
T0.874****0.693****0.148-0.276
11KT0.419*0.1590.1090.276-
Males
17OHPA411OHA4T11KT
Patients 17OHP-0.798****0.633***0.3310.773****
A40.798****-0.659**0.555**0.637***
11OHA40.633***0.659**-0.2240.613***
T0.3310.555**0.224-0.016
11KT0.773****0.637***0.613***0.016-
17OHPA411OHA4T11KT
Controls17OHP-0.780***0.2760.622**0.203
A40.780***-0.3400.814****0.249
11OHA40.2760.340--0.0100.806****
T0.622**0.814****-0.010--0.032
11KT0.2030.2490.806****-0.032-
Females
17OHPA411OHA4T11KT
Patients 17OHP-0.695****0.564*0.614***0.737****
A40.695****-0.450*0.868****0.697****
11OHA40.564**0.450*-0.470*0.764****
T0.614***0.868****0.470*-0.631***
11KT0.737****0.697****0.764****0.631***-
17OHPA411OHA4T11KT
Controls17OHP-0.597**0.2330.874****0.419
A40.597**-0.3670.693****0.159
11OHA40.2330.367-0.1480.109
T0.874****0.693****0.148-0.276
11KT0.419*0.1590.1090.276-

Spearman’s correlation coefficient r. P value ≤ 0.05 (*), ≤0.01 (**), ≤0.001 (***), ≤0.0001 (****).

Abbreviations: 11KT, 11-ketotestosterone; 11OHA4, 11β-hydroxyandrostenedione; 17OHP, 17-hydroxyprogesterone; A4, androstenedione; T, testosterone.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close